Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II Maintenance Enzalutamide After Docetaxel plus Androgen-Deprivation Therapy in Metastatic Castration-Naïve Prostate Adenocarcinoma
KCT0009086Phase 2Not yet recruiting
- Sponsor
- Samsung Medical Center
- Start
- Jan 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of enzalutamide in prostate adenocarcinoma, sponsored by Samsung Medical Center. Planned start Jan 2024; status: not yet recruiting.
02
Drugs
enzalutamide
03
Conditions
prostate adenocarcinoma
Beyond the preview
Go deeper on KCT0009086.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0009086.